CN101374426A - 可溶性膳食纤维对抗肌萎缩的用途 - Google Patents
可溶性膳食纤维对抗肌萎缩的用途 Download PDFInfo
- Publication number
- CN101374426A CN101374426A CNA2006800529184A CN200680052918A CN101374426A CN 101374426 A CN101374426 A CN 101374426A CN A2006800529184 A CNA2006800529184 A CN A2006800529184A CN 200680052918 A CN200680052918 A CN 200680052918A CN 101374426 A CN101374426 A CN 101374426A
- Authority
- CN
- China
- Prior art keywords
- composition
- purposes
- oligosaccharides
- fiber
- carbohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 18
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 14
- 206010028289 Muscle atrophy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 50
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 46
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 24
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 24
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 150000004676 glycans Chemical class 0.000 claims abstract description 4
- 239000000835 fiber Substances 0.000 claims description 39
- 150000001720 carbohydrates Chemical class 0.000 claims description 25
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 235000018102 proteins Nutrition 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 230000018044 dehydration Effects 0.000 claims description 10
- 238000006297 dehydration reaction Methods 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 150000003214 pyranose derivatives Chemical group 0.000 claims description 6
- 229960003487 xylose Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- 230000002641 glycemic effect Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000001076 sarcopenia Diseases 0.000 claims description 3
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical group O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 13
- 230000007062 hydrolysis Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 8
- -1 wood sugar oligosaccharide Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 229920002907 Guar gum Polymers 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 239000000665 guar gum Substances 0.000 description 6
- 235000010417 guar gum Nutrition 0.000 description 6
- 229960002154 guar gum Drugs 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- 229920000926 Galactomannan Polymers 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 150000002243 furanoses Chemical group 0.000 description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 244000182067 Fraxinus ornus Species 0.000 description 3
- 235000002917 Fraxinus ornus Nutrition 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940118199 levulan Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 150000001323 aldoses Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 1
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- FZWBNHMXJMCXLU-YRBKNLIBSA-N manninotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-YRBKNLIBSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 235000021290 n-3 DPA Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pediatric Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Abstract
包含膳食纤维的营养组合物用于治疗肌萎缩，条件是所述膳食纤维包含至少30wt.％半乳寡聚糖或者包含主要具有脱水吡喃糖单位并具有3－10个单位的链长的其他寡糖。所述组合物还可包含其他寡糖或多糖，尤其是大部分为脱水呋喃糖单位的多糖。
Description
技术领域
本发明涉及包含难消化的寡糖的营养组合物或药物组合物用于治疗肌萎缩或降低其发病率的用途。
发明背景
严重的体重减轻且特别是肌萎缩是在患有疾病、病症和创伤的患者中大范围发生的严重现象。慢性疾病中的肌萎缩(简称MW)被定义为在一个月内体重自然减轻超过5％。如果以更缓的速率但在更长的时间内发生瘦体重(简称LBM)减轻，则本发明人指的是慢性肌萎缩(简称CMW)，特别是如果在6个月内体重减轻超过10％。通常在创伤或手术的恢复中观察到MW。通常在严重疾病如癌症、AIDS、COPD、糖尿病和心力衰竭中观察到CMW。肌萎缩的速率与升高的发病率和死亡率相关。认为由疾病引起的肌萎缩的原因是多因素的。营养不良，特别是蛋白质-能量的营养不良也可能引起肌萎缩。如EP 0721742中提出的，通过提供额外的蛋白质或能量可以治疗或预防尤其是后一类型的营养不良。
少肌症(sarcopenia，简称SP)是伴随衰老发生的瘦肌肉质量、强度和功能的自然下降。SP增加了老人的功能性容量损失的风险，这不一定涉及疾病。
膳食纤维被频繁用于引发体重减轻。膳食纤维降低血液中的餐后葡萄糖水平并具有饱足感。因此，在营养不良、体重减轻和肌萎缩的情况下，一般不推荐给予大量膳食纤维。膳食纤维还被包含在用于影响结肠菌群的临床营养剂中，且已主张特定的纤维或其混合物降低全身性感染的速率(如在WO 02/26242中)，提高特异性免疫相关的参数(如在EP-B 1105002中)，或者降低动物中的选定肿瘤的生长速率(如在Taper H.，J Nutr.，129(1999)，1488-1491中)。
许多类型的膳食纤维已被用于制备营养品。当存在于口中时，其中几种大大增加粘度，其他的具有差的溶解度或者产生沙样感觉。因此，需要这样的营养品，它们能容易地被患有肌萎缩或慢性肌萎缩的人们所消耗，并且对抗或预防肌萎缩，而没有现有技术的产品的缺点，如液体饮料的高粘度。
WO 2004/026294公开了游离的必需氨基酸(包括亮氨酸)的混合物用于改善肿瘤诱导的体重减轻的效果的用途。所述混合物可与其他成分如完整蛋白质、ω-3脂肪酸和可溶性纤维如水解的瓜尔胶混合。
US 6,387,883教导通过给药ω-3脂肪酸、支链氨基酸和可能包括膳食纤维的其他成分来治疗恶病质和厌食症。
US 2005/153019涉及通过提供包含乳清蛋白、ω-3脂肪酸、碳水化合物、维生素等的组合物来刺激机体的蛋白质合成。所述组合物还可以包含益生的纤维(例如果糖寡聚糖)用于促进双歧杆菌的生长，但这样的组合物未被进一步说明。
US 5,444,054教导在溃疡性结肠炎或绞痛炎症(colic inflammation)的情况下，使用ω-3脂肪酸EPA和DHA与难消化的碳水化合物(如阿拉伯胶和果糖寡聚糖和木糖寡聚糖)的组合来改善营养状况的方法。
发明内容
令人惊讶地发现，包含至少30wt.％的难消化的寡糖的膳食纤维和包含这样的纤维的营养品或药品满足这种需要。这不同于现有技术中频繁使用纤维引发体重减轻。本发明所用的难消化的可溶性寡糖具有3-10个脱水单糖单位的链长。
在优选实施方案中，所述难消化的寡糖的脱水单糖单位大部分是脱水吡喃糖单位。这些脱水吡喃糖单位具有六元环结构，并包括醛糖的脱水形式如半乳糖、甘露糖、木糖以及它们的脱氧形式(例如岩藻糖和鼠李糖)、它们的酸形式如半乳糖醛酸酯和葡糖醛酸酯、它们的氨基形式和N-酰氨基形式(如半乳糖胺)、以及它们的更高级的同系物(例如神经氨酸和其他唾液酸)。它们还可以包括脱水葡萄糖单位及其衍生物，只要所述寡糖本质上仍是难消化的。因此，所述寡糖不含超过两个或优选少于两个α-1，4-连接的脱水葡萄糖单位。而且，所述寡糖中可存在少量其他脱水单糖单位，例如脱水阿拉伯糖单位(无论是以吡喃糖苷形式还是呋喃糖苷形式)。通过在一个脱水单糖的第一(异头)碳原子与相邻脱水单糖部分的第2、3、4个(或在己糖的情况下为第6个)碳原子之间藉由氧原子的α-或β-连接可将所述脱水单糖单位彼此连接，正如已在本领域中对于许多难消化的碳水化合物中进行描述。
此实施方案的优选寡糖是半乳寡聚糖、甘露寡聚糖和/或木糖寡聚糖。它们可以是均聚寡糖，或者是包含半乳糖、甘露糖和/或木糖单位的异聚寡糖，所述异聚寡糖还可包含10-35％的脱水葡萄糖和/或脱水阿拉伯糖单位、脱水岩藻糖、脱水葡萄糖胺和/或N-乙酰基-脱水葡萄糖胺单位，它们优选地在末端位置。尽管异聚体是有效的，但从成本有效的角度看，有时优选包括吡喃寡聚糖的同系物变体。在上下文中，仅在其末端位置具有单个不同单糖单位的寡糖(例如半乳寡聚糖中的葡萄糖单位)仍被认为是均低聚物(homo-oligomer)。
在另一实施方案中，所述难消化的寡糖的脱水单糖单位大部分是脱水呋喃糖单位。这些脱水呋喃糖单位具有五元环结构，并包括醛糖或酮糖的脱水形式如果糖或阿拉伯糖、以及它们的脱氧形式、它们的氨基形式和N-酰氨基形式、以及它们的更高级的同系物。它们还可以包括脱水葡萄糖单位及其衍生物，只要所述寡糖本质上仍是难消化的。因此，这些寡糖不含超过两个或优选少于两个α-1，4-连接的脱水葡萄糖单位。而且，在这些寡糖中可存在少量其他脱水单糖单位，无论是以吡喃糖苷形式还是呋喃糖苷形式。
在本发明的另一优选实施方案中，所述寡糖由两类组成，一类大部分是脱水吡喃糖单位，另一类大部分是脱水呋喃糖单位，它们各自如上文所定义。在该实施方案中，所述膳食纤维包含至少40wt.％，优选至少50wt.％、更优选至少60wt.％的完全难消化的寡糖，所述完全难消化的寡糖包含30-98wt.％，优选50-96wt.％的第一类(吡喃糖系)寡糖和2-50wt.％，优选4-30wt.％的第二类(呋喃糖系)寡糖。这些重量百分数基于所述纤维组合物的重量。第一类和第二类之间的重量比优选为98:2至2:98，更优选97:3至10:90，最优选96:4至50:50。
可以通过本领域熟知的方法获得用于本发明的寡糖。根据第一种方法，可通过化学(酸)水解或优选酶法水解，将合适的多糖选择性地或随机水解。例如可以在pH 3-6，用β-甘露聚糖酶和/或α-半乳糖苷酶对瓜尔胶、刺槐豆胶、角豆树胶或他拉半乳甘露聚糖进行处理，以产生低粘度的产物，尤其是在通过α-半乳糖苷酶的作用从聚合物中除去部分或全部半乳糖时。作为另一实例，通过合适的(内-β-1，3-)半乳聚糖，任选地与阿拉伯糖苷酶组合以除去阿拉伯糖侧链，可将半乳聚糖和阿拉伯半乳聚糖水解，并且使用(β-)木聚糖酶，任选地与阿拉伯糖苷酶和/或半乳糖醛酸糖苷酶(galacturonidase)组合，可将木聚糖和阿拉伯木聚糖(arabinoxylan)水解。通过选择适当的水解条件，可以获得具有需要链长的低粘度寡糖。通常，通过内型糖酵解水解，可以获得异聚寡糖如半乳糖基-低聚甘露聚糖、阿拉伯糖基-低聚半乳聚糖和阿拉伯糖基-低聚木聚糖，其中没有除去侧链，并且可以通过酶法除去侧链来获得大量均聚寡糖。在半乳甘露聚糖如瓜尔胶的水解产物的情况下，甘露二糖、甘露三糖和低聚半乳甘露糖的量优选超过所述寡糖的20％，优选为40-100％。作为进一步的实例，可以原样使用菊粉或者在化学水解或酶法水解后使用之；这样的水解得到具有末端葡萄糖单位的果糖寡聚糖和纯的果糖寡聚糖。
根据第二种通用方法，通过用一种或多种合适的酶或具有这些酶的一种或多种微生物或酵母将合适的底物酶法转糖基，可以制备(异聚)寡糖。合适的底物的实例为单己糖或二己糖、乳糖或纤维或它们的部分水解产物(如瓜尔胶的水解产物)的溶液。
特别地，半乳寡聚糖(GOS)非常适于制备有效的营养组合物或药物组合物。合适的半乳寡聚糖是可商购的，包括从乳糖通过与β-半乳糖苷酶反应制备的寡糖。优选地，这些半乳寡聚糖包含至少67wt.％，尤其是至少80wt.％的具有3至5个单位的链长的寡糖，无论是单糖还是二糖如乳糖。
对于体重80kg的人，所述可溶性膳食纤维组合物的有效剂量为0.1-20、优选0.6-10、更优选0.8-5克/剂。对于具有不同体重的人(包括婴儿)，按比例降低所述剂量。关于每千克体重的剂量，优选的每日剂量为1.2-250mg/kg/天，优选7.5-130mg/kg/天，更优选10-65mg/kg/天。
所述可溶性纤维部分的其他成分可以包括非寡糖，如可溶的和可发酵的以及不可发酵的纤维，包括来自呋喃糖型的多糖。实例为菊粉、其他果糖多糖(果聚糖)、适度水解的果胶和其他树胶，如葡甘露聚糖(如Konjac)、半乳甘露聚糖(如瓜尔胶)、黄原胶和阿拉伯胶。这些多糖(具有超过10个单位的链长(DP))可以占所述可溶性纤维组合物的高达70wt.％。然而，优选所述纤维组合物包含至少50％，更优选至少70％，高达例如95％或甚至98％或100％寡糖，尤其是上文定义的半乳寡聚糖、甘露寡聚糖、木糖寡聚糖。剩余部分可以由一种或多种可溶性多糖纤维(尤其是果聚糖型)组成。除了可溶性纤维部分，可以将不溶性纤维如抗性淀粉和不溶性可发酵的以及不可发酵的纤维如纤维素引入纤维掺混物中。优选的是，所述不溶性纤维占所述可溶性纤维部分的低于50wt.％，尤其在其5-25wt.％之间。
在具体实施方案中，所述可溶性纤维组合物可以包含2-50wt.％，特别是5-30wt.％的果聚糖(DP≥3)和/或2-35wt.％，特别是5-25wt.％的其他可溶性多糖，如水解的半乳甘露聚糖(具有超过10个脱水单糖单位)。
可被有益地包含在所述组合物中的其他成分是特异性蛋白质、脂质、碳水化合物和微量成分。
所述组合物可以是液体、半固体或固体。在液体溶液中，本发明的寡糖的引入得到非粘性的产品，当包含有效量时，在100sec-1剪切速率和20℃，具有低于70，优选1-40，更优选2-30MPa.s的粘度，这使得所述溶液适合用作管饲。在液体中，每个包装会包含有效剂量。对于管饲，假定为2000ml/天，每天分两部分给予。当所述液体产品用作补充剂时，例如以每份200ml，可相应计算浓度。通常，有效寡糖的浓度会大大低于15，例如0.05-10，优选0.5-9，更优选1-8％重量/体积。当所述产品为半固体形式如布丁或固体形式如棒时，所述产品会被用作补充剂，每个包装为25-200ml。因此所述浓度会为每25-200g产品0.1-20g。按能量计，所述可溶性纤维组合物的含量优选为每419KJ(100kal)0.5-10g，更优选每419KJ(100kcal)1-4g。
液体组合物的能量含量通常会为2.5-16.8，优选5.0-16.8，更优选5.4-8.4且最优选6.3-8.0KJ/ml(0.6-4.0，优选1.2-4.0，更优选1.3-2.0且最优选1.5-1.9kcal/ml)。
优选的是，本发明的营养组合物包含至少一种蛋白质部分。纤维部分与蛋白质部分之间的重量比优选为5:95至75:25，更优选为10:90至50:50。
基于总的氨基酸，蛋白质部分应优选包含超过45wt％，优选48-70wt％，更优选52-65wt％的必需氨基酸。必需氨基酸是甲硫氨酸、亮氨酸、异亮氨酸、缬氨酸、苯丙氨酸、色氨酸、组氨酸、赖氨酸和苏氨酸。液体产品中必需氨基酸的量通常会超过每100ml4.75g，优选4.9-9.0g，更优选5.1-7g。
特别地，基于氨基酸的总和，优选亮氨酸+异亮氨酸的量超过18.0wt％，且更优选18.5-25wt％。亮氨酸的量优选超过11.0wt％，更优选超过11.4wt％，最优选为12.2-20wt.％。支链氨基酸的量通常会超过每100ml液体产品2.9g，优选3.0-4.0g，更优选3.0-3.4g。
蛋白质部分的能量贡献优选地为所述营养组合物的25-75en％，更优选26-60en％，最优选26-50en％。完整蛋白质部分的能量贡献优选地为所述营养组合物的17-40en％，更优选19-30en％，最优选20-29en％。所述蛋白质部分应该优选包含超过10％，更优选20-60％的完整乳清蛋白或其肽片段。
所述脂质部分应包含ω-3型长链脂肪酸。长链表示至少18个碳原子。特别优选的是具有20-26个碳原子并具有4个或更多个不饱和键的脂肪酸。长链多不饱和脂肪酸的总量应超过所有脂肪酸总和的10wt.％，优选15-50wt.％，更优选17-42wt.％，特别是18-42wt.％。ω-3长链多不饱和脂肪酸(LCP’s)(如：α-亚油酸、十八碳四烯酸、二十碳五烯酸(EPA)、二十二碳五烯酸(DPA)、二十二碳六烯酸(DHA)和二十四碳六烯酸(THA))与可溶性纤维之间的重量比优选为90:10至5:95，更优选80:20至15:85。长链多不饱和脂肪酸与可溶性纤维以及任选的其他成分的组合可被适当地用作食品补充剂。优选的是，所述可溶性纤维包含半乳寡聚糖、甘露寡聚糖和/或木糖寡聚糖，尤其是水平为例如可溶性纤维的至少50％w/w的半乳寡聚糖。所述脂质部分的能量贡献优选为营养组合物的15-45en％、更优选20-35en％。
所述碳水化合物部分可以包含葡萄糖、麦芽糖糊精、淀粉和/或其他糖。在优选实施方案中，所述碳水化合物部分包含5-50wt％的核糖、尤其是8-25wt.％的核糖以预防肌萎缩。基于所述可溶性纤维组合物，核糖优选以9:1至1:9，更优选4:1至1:4的重量比存在。该组合可以用作食品补充剂。优选的是，这样的补充剂还包含每份核糖1-19份的量的其他可消化的碳水化合物。在还包含脂质和/或蛋白质的营养组合物中，可消化的碳水化合物部分的能量贡献优选为组合物的15-55en％，更优选25-50en％。
还优选的是，所述碳水化合物部分包含乳糖。如果存在，那么乳糖的量超过所述可消化的碳水化合物部分的2wt.％，更优选3-40wt.％，最优选10-30wt％。有用的碳水化合物组合物可以包含3-40wt.％、优选5-30wt.％的如上文所述的可溶性纤维组合物和3-40wt.％，优选5-30wt.％的核糖和/或5-40wt.％，优选8-30wt.％的乳糖，以及优选20-80wt.％，更优选35-70wt.％的其他可消化的碳水化合物。
与现有技术的知识相反，为了实现降低肌萎缩速率或甚至增加体重，包含具有低升糖指数的可用碳水化合物部分是重要的。将可用碳水化合物部分定义为具有低升糖指数(GI)，其值低于葡萄糖值的70％。所述碳水化合物部分应优选地包含超过20wt.％，更优选40-80wt.％的这些碳水化合物。低GI糖包括乳糖、海藻糖、异麦芽寡聚糖(大部分为α-1，6葡萄糖单位的寡糖)。
还优选包含少量甜糖以提高患者的食物消耗。甜度小于蔗糖甜度的70％的糖的量应超过可用碳水化合物部分的20wt.％。特别地，该量为25-60wt.％。低甜度的糖包括帕拉金糖(异麦芽酮糖)、麦芽糖糊精DE2-47、半乳糖、甘露糖、乳糖和海藻糖。可选地，选自半乳糖、甘露糖、其他含有葡萄糖的二糖的低GI和/或低甜度糖比蔗糖和麦芽糖(包括乳糖、海藻糖和帕拉金糖)和异麦芽寡聚糖的总比例因此优选为20-80wt.％，更优选25-60wt.％。
通常包含人类适当进食所需的所有矿物质和微量成分。通常每日剂量包含推荐的每日量的0.5-1.5倍，除了以推荐的每日量的1-4倍包含叶酸类(尤其是300-1200μg/天或50-1000μg、尤其是60-600μg/g可溶性纤维)。
实施例1
材料和方法
使用雄性CD2F1小鼠(BALB/c x DBA/2，Harlan，荷兰)，并用C-26腺癌细胞诱导荷瘤组(TB)的恶病质，而对照小鼠(C)接受假注射(shaminjection)。在试验1中，食物由51％半乳寡聚糖(GOS)和果糖多糖(9:1)、19％麦芽糖糊精、16％乳糖和14％葡萄糖组成。在试验2中，用另外的GOS代替FOS。反式半乳寡聚糖的GOS喷雾干燥粉末的聚合度(dp)为3-8(VivinalGOS，Borculo Domo，Zwolle，荷兰)且FOS具有高聚合度(Raftiline HP，Orafti，Wijchen，荷兰；平均dp>23)。在接种肿瘤细胞后，切除肿瘤块和骨骼肌(趾长伸肌(EDL)和比目鱼肌)并称重。
试验1
-对照小鼠 ＝C
-荷瘤小鼠 ＝TB
-荷瘤+GOS/FOS ＝TB-Gos Fos
试验2
-对照小鼠 ＝C
-荷瘤小鼠 ＝TB
-荷瘤+GOS ＝TB-Gos
结果
下表代表试验1和2的肌肉质量(mg，+相对于C的损失％)。
| 试验1 | m.EDL | m.比目鱼肌 |
| CTBTB-Gos Fos由Gos/Fos引起的降低的质量减轻 | 9.5±0.8*7.7±0.6(-19.0％)8.2±0.6(-13.7％)*28％ | 6.5±0.6*5.5±0.7(-15.4％)5.8±0.9(-10.6％)30％ |
| 试验2 | ||
| CTBTB-Gos由Gos/Fos引起的降低的质量减轻 | 9.8±0.8*7.7±0.6(-21.4％)8.2±0.6(-16.3％)*26％ | 7.5±0.7*5.6±0.4(-25.3％)6.2±0.6(-17.3％)*32％ |
从本发明的数据中推断，半乳寡聚糖使得肿瘤恶病质中的肌肉损失变弱。星号(*)表示TB组的统计学差异(P<0.025)。
实施例2：
制备液体配方用于患有慢性肌萎缩的患者。其每100ml含有：
能量 658kJ(157kcal)
蛋白质[8.2g酪蛋白和乳清，1.8g Leu] 10.0g
脂质[海洋生物油(marine oil)，植物性] 5.3g
a.EPA 0.56g
b.DHA 0.27g
碳水化合物 17.4g
a.蔗糖 4.21g
b.麦芽糖糊精 8.42g
c.海藻糖 4.21g
d.乳糖 0.59g
纤维 2.05g
a.菊粉DP>20 0.1g
b.水解的菊粉DP<20 0.08g
c.GOS 1.53g
d.抗性淀粉 0.05g
e.纤维素 0.31g
实施例3：
制备液体配方用于患有慢性肌萎缩的患者。该配方每100ml含有：
能量 662kJ(158kcal)
蛋白质[酪蛋白，乳清+1g Leu，0.5g Met，0.5g Arg] 10.0g
脂质[海洋生物油，植物性] 5.3g
碳水化合物[糖掺混物] 17.5g
纤维[GOS+聚果糖9:1] 2.1g
灰分 1.2g
实施例4：
制备液体配方用于患有慢性肌萎缩的患者。该配方每100ml含有：
能量 587kJ(140kcal)
蛋白质[酪蛋白+0.9g Leu，0.5g Ile，0.2g Val] 9g
脂质 5.0g
碳水化合物(10wt.％游离核糖) 15g
纤维[水解的瓜尔胶+GOS比率3:7] 1.5g
矿物质/痕量元素/包含60μg叶酸的维生素 2.0g
实施例5：
每100ml用于患有慢性肌萎缩的患者的液体配方含有：
蛋白质[酪蛋白6.1+乳清2.9+游离Leu1.1] 10.1g
脂质[EPA0.6，DHA0.2，ω-3/ω-6＝1.16，
PUFA′s2.5；MUFA1.5；饱和的0.76] 5.6g
可消化的碳水化合物[蔗糖3.92，乳糖0.7
麦芽糖糊精7.84；海藻糖3.92] 16.4g
纤维[水解的菊粉DP<20 0.2+GOS 1.8] 2.0g
矿物质/痕量元素/维生素
Claims (15)
1.可溶性膳食纤维用于制备治疗肌萎缩和/或慢性肌萎缩和/或少肌症或降低它们的发病率的营养组合物或药物组合物的用途，所述膳食纤维包含至少30wt.％的具有3-10个脱水单糖单位的链长的寡糖。
2.根据权利要求1的用途，其中所述膳食纤维包含至少30wt.％的其中所述脱水单糖单位大部分是脱水吡喃糖单位的寡糖，所述脱水吡喃糖单位选自：半乳糖、甘露糖、木糖、它们的脱氧形式、氨基形式和N-酰氨基形式。
3.根据权利要求1或2的用途，其中所述膳食纤维包含30-96wt.％的其中所述脱水单糖单位大部分是脱水半乳糖单位的寡糖和4-50wt.％的其中所述脱水单糖单位大部分是脱水果糖单位的寡糖和/或多糖。
4.根据权利要求1-3中任一项的用途，其中所述膳食纤维包含50-100wt.％，优选70-98wt.％的所述寡糖。
5.根据权利要求1-4中任一项的用途，其中所述肌萎缩与肿瘤、手术、创伤或炎症相关。
6.根据权利要求5的用途，其中所述肿瘤是肝、胰、肺、皮肤、食管、脑、头与颈的肿瘤。
7.根据权利要求1-6中任一项的用途，其中所述组合物是包含可消化的碳水化合物、脂肪和蛋白质的营养组合物。
8.根据权利要求7的用途，其中所述营养组合物是在20℃，在100sec-1的剪切速率下，具有小于35Mpa.s的粘度的液体组合物。
9.根据权利要求7或8的用途，其中所述营养组合物具有在5.0至16.8kJ/ml(1.2至4.0kcal/ml)之间、优选在5.4至8.4KJ/ml(1.3至2.0kcal/ml)之间的能量密度。
10.根据前述权利要求中任一项的用途，其中所述组合物还包含支持核苷酸合成和叶酸代谢的成分，尤其是每克纤维组合物50-1000μg的量的叶酸。
11.根据前述权利要求中任一项的用途，其中所述组合物还包含具有小于葡萄糖的升糖指数的70％的升糖指数的碳水化合物部分。
12.食品补充剂，其包含10-90wt.％的如权利要求1-4中任一项所定义的可溶性纤维组合物以及90-10wt.％的核糖。
13.碳水化合物组合物，其包含3-40wt.％的如权利要求1-4中任一项所定义的可溶性纤维组合物、3-40wt.％的核糖、5-40wt.％的乳糖和20-80wt.％的其他可消化的碳水化合物。
14.食品补充剂，其包含10-95wt.％的如权利要求1-4中任一项所定义的可溶性纤维组合物以及5-90wt.％的ω-3脂肪酸，所述可溶性纤维包含半乳寡聚糖。
15.营养组合物，其包含如权利要求1-4中任一项所定义的可溶性纤维组合物和蛋白质部分，所述纤维组合物与所述蛋白质部分的重量比为5：95至75：25，所述蛋白质部分包含至少48wt.％的必需氨基酸，所述可溶性纤维包含半乳寡聚糖。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05112336 | 2005-12-16 | ||
| EP05112336.2 | 2005-12-16 | ||
| PCT/NL2006/050320 WO2007069900A1 (en) | 2005-12-16 | 2006-12-18 | Use of soluble dietary fibres against muscle wasting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210382032.3A Division CN102948659B (zh) | 2005-12-16 | 2006-12-18 | 碳水化合物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101374426A true CN101374426A (zh) | 2009-02-25 |
| CN101374426B CN101374426B (zh) | 2012-11-28 |
Family
ID=36028309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210382032.3A Active CN102948659B (zh) | 2005-12-16 | 2006-12-18 | 碳水化合物组合物 |
| CN2006800529184A Active CN101374426B (zh) | 2005-12-16 | 2006-12-18 | 可溶性膳食纤维对抗肌萎缩的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210382032.3A Active CN102948659B (zh) | 2005-12-16 | 2006-12-18 | 碳水化合物组合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8143235B2 (zh) |
| EP (1) | EP1965669B1 (zh) |
| JP (1) | JP2009519328A (zh) |
| CN (2) | CN102948659B (zh) |
| AT (1) | ATE441333T1 (zh) |
| AU (1) | AU2006325591B2 (zh) |
| BR (1) | BRPI0619947B1 (zh) |
| CA (1) | CA2633292C (zh) |
| DE (1) | DE602006008985D1 (zh) |
| DK (1) | DK1965669T3 (zh) |
| ES (1) | ES2332149T3 (zh) |
| IL (1) | IL192219A (zh) |
| NZ (1) | NZ569169A (zh) |
| PL (1) | PL1965669T3 (zh) |
| RU (1) | RU2450815C2 (zh) |
| WO (1) | WO2007069900A1 (zh) |
| ZA (1) | ZA200805905B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103476275A (zh) * | 2011-04-18 | 2013-12-25 | 雀巢产品技术援助有限公司 | 包含α-羟基异己酸的营养组合物 |
| CN106387923A (zh) * | 2016-09-07 | 2017-02-15 | 中国农业大学 | 一种富含半乳甘露聚糖的可溶性膳食纤维及其制备方法 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| JP4610499B2 (ja) * | 2006-02-27 | 2011-01-12 | ポーラ化成工業株式会社 | 食品組成物 |
| WO2009153064A2 (en) * | 2008-06-19 | 2009-12-23 | N.V. Nutricia | Liquid nutritional composition for bariatric surgery patients |
| WO2009157759A1 (en) | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
| WO2010002242A1 (en) | 2008-07-02 | 2010-01-07 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
| BRPI0915974A2 (pt) * | 2008-07-18 | 2017-05-30 | Hill´S Pet Nutrition Inc | métodos para modular funções biológicas, para tratar um animal sofrendo de um distúrbio ou doença, para alterar a expressão de pelo menos um peptídeo em um mamífero, e para triar um ou mais compostos de teste para habilidade para alterar a expressão de pelo menos um gene de interesse em um mamífero |
| SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
| WO2010143939A1 (en) * | 2009-06-09 | 2010-12-16 | N.V. Nutricia | Nutrition for improving muscle strength in elderly |
| EP2563372A4 (en) | 2010-04-28 | 2013-10-02 | Ritter Pharmaceuticals Inc | PREBIOTIC FORMULATIONS AND METHODS OF USE |
| WO2014007606A1 (en) * | 2012-07-05 | 2014-01-09 | N.V. Nutricia | Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour |
| ES2402643B1 (es) | 2012-12-24 | 2014-01-24 | Universitat De Lleida | Combinación de fibra anticolesterolémica |
| MY186844A (en) | 2014-07-09 | 2021-08-25 | Cadena Bio Inc | Oligosaccharide compositions and methods for producing thereof |
| WO2016029113A1 (en) * | 2014-08-22 | 2016-02-25 | Abbott Laboratories | Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate |
| JP2018517677A (ja) | 2015-04-23 | 2018-07-05 | カレイド・バイオサイエンシズ・インコーポレイテッド | グリカン治療剤及び治療方法 |
| KR102548553B1 (ko) * | 2016-04-14 | 2023-06-27 | 듀폰 뉴트리션 바이오사이언시즈 에이피에스 | 제지방 체중을 증가시키기 위한 비피더스균 |
| EP3357352B1 (de) | 2017-02-02 | 2021-03-24 | artgerecht GmbH | Zusammensetzung mit aminosäuren |
| DE102017201713A1 (de) * | 2017-02-02 | 2018-08-02 | artgerecht GmbH | Zusammensetzung mit Aminosäuren |
| AU2019376144A1 (en) * | 2018-11-08 | 2021-05-13 | Dsm Ip Assets, B.V. | Methods of supporting gastrointestinal homeostasis |
| AU2019376668A1 (en) * | 2018-11-08 | 2021-05-13 | Dsm Ip Assets, B.V. | Methods of selectively modulating gastrointestinal microbial growth |
| TW202108007A (zh) * | 2019-05-24 | 2021-03-01 | 比利時商科舒克拉 格魯普瓦爾科迎有限公司 | 包含纖維及蛋白質之組合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5589468A (en) | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
| US5641531A (en) * | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| ATE218065T1 (de) * | 1996-08-09 | 2002-06-15 | Mannatech Inc | Zusammensetzungen auf pflanzliicher kohlenhydratbasis als nahrungsergänzungsstoffe |
| US5776524A (en) | 1996-10-30 | 1998-07-07 | The Iams Company | Process for treating small intestine bacterial overgrowth in animals |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| DE19836339B4 (de) * | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
| GB2364642B (en) * | 2000-01-07 | 2004-10-27 | Bioenergy Inc | Compositions for enhancing the immune response |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US6592863B2 (en) | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
| US7431939B1 (en) | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
| JP2003137790A (ja) * | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| JP2004051942A (ja) * | 2002-05-29 | 2004-02-19 | Daicel Chem Ind Ltd | 分散体及びそれを用いた成形体の製造方法 |
| US20040087490A1 (en) | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
| GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| DK1643861T3 (da) * | 2003-07-15 | 2011-07-25 | Nestec Sa | Fiber- og kalorierig flydende næringssammensætning til tarmsundhed hos ældre patienter |
| CN1871015B (zh) * | 2003-10-24 | 2010-06-16 | 努特里奇亚有限公司 | 免疫调节性寡糖 |
| NZ546785A (en) * | 2003-10-24 | 2009-07-31 | Nutricia Nv | Immunemodulating oligosaccharides |
| AU2006237738B2 (en) * | 2005-04-21 | 2011-09-29 | N.V. Nutricia | Nutritional supplement for HIV patients |
| WO2009157759A1 (en) | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
-
2006
- 2006-12-18 CA CA2633292A patent/CA2633292C/en active Active
- 2006-12-18 AU AU2006325591A patent/AU2006325591B2/en active Active
- 2006-12-18 EP EP06824315A patent/EP1965669B1/en active Active
- 2006-12-18 JP JP2008545522A patent/JP2009519328A/ja active Pending
- 2006-12-18 NZ NZ569169A patent/NZ569169A/en unknown
- 2006-12-18 ZA ZA200805905A patent/ZA200805905B/xx unknown
- 2006-12-18 DK DK06824315T patent/DK1965669T3/da active
- 2006-12-18 RU RU2008129102/15A patent/RU2450815C2/ru active
- 2006-12-18 CN CN201210382032.3A patent/CN102948659B/zh active Active
- 2006-12-18 BR BRPI0619947-0A patent/BRPI0619947B1/pt active IP Right Grant
- 2006-12-18 ES ES06824315T patent/ES2332149T3/es active Active
- 2006-12-18 US US12/097,667 patent/US8143235B2/en active Active
- 2006-12-18 WO PCT/NL2006/050320 patent/WO2007069900A1/en active Application Filing
- 2006-12-18 DE DE602006008985T patent/DE602006008985D1/de active Active
- 2006-12-18 PL PL06824315T patent/PL1965669T3/pl unknown
- 2006-12-18 CN CN2006800529184A patent/CN101374426B/zh active Active
- 2006-12-18 AT AT06824315T patent/ATE441333T1/de not_active IP Right Cessation
-
2008
- 2008-06-16 IL IL192219A patent/IL192219A/en active IP Right Grant
-
2012
- 2012-03-02 US US13/411,227 patent/US9555059B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103476275A (zh) * | 2011-04-18 | 2013-12-25 | 雀巢产品技术援助有限公司 | 包含α-羟基异己酸的营养组合物 |
| CN106387923A (zh) * | 2016-09-07 | 2017-02-15 | 中国农业大学 | 一种富含半乳甘露聚糖的可溶性膳食纤维及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE441333T1 (de) | 2009-09-15 |
| IL192219A (en) | 2011-08-31 |
| NZ569169A (en) | 2012-01-12 |
| EP1965669A1 (en) | 2008-09-10 |
| AU2006325591B2 (en) | 2012-07-12 |
| CN102948659A (zh) | 2013-03-06 |
| CA2633292A1 (en) | 2007-06-21 |
| CA2633292C (en) | 2015-04-28 |
| JP2009519328A (ja) | 2009-05-14 |
| ZA200805905B (en) | 2009-10-28 |
| RU2450815C2 (ru) | 2012-05-20 |
| WO2007069900A1 (en) | 2007-06-21 |
| BRPI0619947A2 (pt) | 2011-10-25 |
| EP1965669B1 (en) | 2009-09-02 |
| CN101374426B (zh) | 2012-11-28 |
| CN102948659B (zh) | 2014-04-23 |
| US8143235B2 (en) | 2012-03-27 |
| US9555059B2 (en) | 2017-01-31 |
| PL1965669T3 (pl) | 2010-02-26 |
| US20090203573A1 (en) | 2009-08-13 |
| BRPI0619947B1 (pt) | 2023-10-10 |
| IL192219A0 (en) | 2008-12-29 |
| DK1965669T3 (da) | 2009-10-05 |
| US20120165243A1 (en) | 2012-06-28 |
| RU2008129102A (ru) | 2010-01-27 |
| ES2332149T3 (es) | 2010-01-27 |
| DE602006008985D1 (de) | 2009-10-15 |
| AU2006325591A1 (en) | 2007-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101374426B (zh) | 可溶性膳食纤维对抗肌萎缩的用途 | |
| JP4509563B2 (ja) | ペクチンを含有するマトリックス形成組成物 | |
| CN101378666B (zh) | 用于平缓葡萄糖反应的碳水化合物组合物 | |
| CN101163415B (zh) | 用于hiv患者的营养补充剂 | |
| CN101925307B (zh) | 高能量液体肠营养组合物 | |
| EP3342413B1 (en) | Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral diarrhoea | |
| CN102264246A (zh) | 液体高脂肪蛋白组合物 | |
| CN101945589A (zh) | 用于改善肠道微生物群的非消化性碳水化合物的用途 | |
| RU2420296C2 (ru) | Композиции, содержащие олигосахариды, для профилактики или лечения инфекций | |
| EP1105002A2 (de) | Kohlenhydratmischungen | |
| CN101262783A (zh) | 用于一类hiv病人的营养补充剂 | |
| BRPI0610786B1 (pt) | Uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia | |
| CN101043822B (zh) | 含有可发酵多糖的组合物 | |
| CA2529491C (en) | Hot liquid fiber product | |
| Sharma et al. | Prebiotics: A review of therapeutic potential | |
| EP1897449A1 (en) | Oral and /or topical compositions | |
| WO2012113677A1 (de) | Prebiotische kohlenhydrat-zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |